Show simple item record

dc.contributor.authorEngelhardt, M
dc.contributor.authorTerpos, E
dc.contributor.authorKleber, M
dc.contributor.authorGay, F
dc.contributor.authorWäsch, R
dc.contributor.authorMorgan, G
dc.contributor.authorCavo, M
dc.contributor.authorvan de Donk, N
dc.contributor.authorBeilhack, A
dc.contributor.authorBruno, B
dc.contributor.authorJohnsen, HE
dc.contributor.authorHajek, R
dc.contributor.authorDriessen, C
dc.contributor.authorLudwig, H
dc.contributor.authorBeksac, M
dc.contributor.authorBoccadoro, M
dc.contributor.authorStraka, C
dc.contributor.authorBrighen, S
dc.contributor.authorGramatzki, M
dc.contributor.authorLarocca, A
dc.contributor.authorLokhorst, H
dc.contributor.authorMagarotto, V
dc.contributor.authorMorabito, F
dc.contributor.authorDimopoulos, MA
dc.contributor.authorEinsele, H
dc.contributor.authorSonneveld, P
dc.contributor.authorPalumbo, A
dc.contributor.authorEuropean Myeloma Network,
dc.date.accessioned2018-07-16T09:26:03Z
dc.date.issued2014-02-01
dc.identifier.citationHaematologica, 2014, 99 (2), pp. 232 - 242
dc.identifier.issn0390-6078
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2070
dc.identifier.eissn1592-8721
dc.identifier.doi10.3324/haematol.2013.099358
dc.description.abstractMultiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B).
dc.formatPrint
dc.format.extent232 - 242
dc.languageeng
dc.language.isoeng
dc.publisherFERRATA STORTI FOUNDATION
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectEuropean Myeloma Network
dc.subjectMultiple Myeloma
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectClinical Trials, Phase III as Topic
dc.subjectAutografts
dc.titleEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
dc.typeJournal Article
rioxxterms.versionofrecord10.3324/haematol.2013.099358
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2014-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfHaematologica
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.publication-statusPublished
pubs.volume99
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)
dc.contributor.icrauthorMorgan, Gareth John


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0